Published in Psychopharmacol Bull on January 01, 1985
Meta-analysis of 32 genome-wide linkage studies of schizophrenia. Mol Psychiatry (2008) 2.07
Further evidence of a dose-response threshold for haloperidol in psychosis. Am J Psychiatry (1995) 2.05
Conversions from clozapine to other antipsychotic drugs. Arch Gen Psychiatry (1995) 1.39
Propranolol treatment of assaultive patients with organic brain disease. A double-blind crossover, placebo-controlled study. J Nerv Ment Dis (1986) 1.07
Treatment with clozapine and its effect on plasma homovanillic acid and norepinephrine concentrations in schizophrenia. Psychiatry Res (1993) 1.07
Progression of cerebroventricular enlargement and the subtyping of schizophrenia. Psychiatry Res (1997) 0.96
Treatment and diagnostic subtype in facial affect recognition in schizophrenia. J Psychiatr Res (1995) 0.93
The effects and effectiveness of gamma-hydroxybutyrate in patients with narcolepsy. J Clin Psychiatry (1985) 0.93
Biogenic amine hypotheses of affective disorders. Life Sci (1979) 0.93
Characterization of human cleaved N-CAM and association with schizophrenia. Exp Neurol (2001) 0.91
Mentoring psychiatric trainees' first paper for publication. Acad Psychiatry (1998) 0.90
Morning amnestic effects of triazolam. Hillside J Clin Psychiatry (1986) 0.86
Dystonic reactions following neuroleptics: time course and proposed mechanisms. Psychopharmacologia (1976) 0.85
Serotonin and impulsive/aggressive behavior in cocaine dependent subjects. Prog Neuropsychopharmacol Biol Psychiatry (1994) 0.84
Pharmacokinetics of red blood cell phenothiazine and clinical effects. Acute dystonic reactions. Arch Gen Psychiatry (1976) 0.84
No evidence for linkage between chromosome 5 markers and schizophrenia. Hum Hered (1990) 0.84
Depression and antidepressant therapy: receptor dynamics. Prog Neuropsychopharmacol Biol Psychiatry (1990) 0.84
Clinical characteristics of Kraepelinian schizophrenia: replication and extension of previous findings. Am J Psychiatry (1996) 0.83
Heterogeneity of the psychoses: is there a neurodegenerative psychosis? Schizophr Bull (1998) 0.83
Lithium response in good prognosis schizophrenia. Am J Psychiatry (1980) 0.82
Heterogeneity of schizophrenia: relationship to latency of neuroleptic response. Psychiatry Res (1991) 0.82
Membrane abnormalities in the psychoses and affective disorders. J Psychiatr Res (1984) 0.81
Drug response patterns as a basis of nosology for the mood-incongruent psychoses (the schizophrenias). Psychol Med (1988) 0.81
Beta-adrenergic receptor function in affective illness. Am J Psychiatry (1979) 0.80
Monoamine distribution in primate brain. I Catecholamine-containing perikarya in the brain stem of Macaca speciosa. J Comp Neurol (1975) 0.80
Therapeutic effects of pindolol on behavioral disturbances associated with organic brain disease: a double-blind study. J Clin Psychiatry (1986) 0.80
Early response to haloperidol treatment in chronic schizophrenia. Schizophr Res (1993) 0.80
Relation of clinical symptoms to apomorphine-stimulated growth hormone release in mood-incongruent psychotic patients. Arch Gen Psychiatry (1986) 0.79
Clinical response and plasma haloperidol levels in schizophrenia. Psychopharmacology (Berl) (1983) 0.79
A biomodal distribution of plasma HVA/MHPG in the psychoses. Psychiatry Res (1997) 0.78
Phenothiazine levels in plasma and red blood cells. Their relationship to clinical improvement in schizophrenia. Arch Gen Psychiatry (1980) 0.78
Neuroleptic drug levels and therapeutic response: preliminary observations with red blood cell bound butaperazine. Am J Psychiatry (1977) 0.78
Monoamine distribution in primate brain-IV. Indoleamine-containing perikarya in the brain stem of Macaca arctoides. Neuroscience (1982) 0.78
'Schizophrenia as a chronic active brain process ...': perhaps, but only in part. Psychiatry Res (1997) 0.78
Phencyclidine-induced stereotyped behavior in monkeys: antagonism by pimozide. Eur J Pharmacol (1978) 0.77
Lithium transport in human fibroblasts: relationship to RBC lithium transport and psychiatric diagnoses. Psychiatry Res (1988) 0.77
Nocturnal growth hormone secretion in schizophrenic patients and healthy subjects. Psychiatry Res (1992) 0.77
Blood-brain barrier to 6-hydroxydopamine: uptake by heart and brain. Life Sci (1975) 0.77
Risk factors for clozapine discontinuation among 805 patients in the VA hospital system. Ann Clin Psychiatry (1995) 0.77
Neuroleptic-induced emotional defecation: effects of scopolamine and haloperidol. Psychopharmacology (Berl) (1989) 0.77
Plasma propranolol levels and their effect on plasma thioridazine and haloperidol concentrations. J Clin Psychopharmacol (1987) 0.77
Monamine distribution in primate brain. II. Brain stem catecholaminergic pathways in Macaca speciosa (arctoides). Brain Res (1976) 0.77
Empirical evaluation of the factorial structure of clinical symptoms in schizophrenia: effects of typical neuroleptics on the brief psychiatric rating scale. Biol Psychiatry (1996) 0.77
Enlargement of cerebral third ventricle in psychotic patients with delayed response to neuroleptics. Biol Psychiatry (1990) 0.77
Growth hormone response to apomorphine and diagnosis: a comparison of three diagnostic systems. Biol Psychiatry (1986) 0.76
Haloperidol plasma and red blood cell levels and clinical antipsychotic response. J Clin Psychopharmacol (1984) 0.76
Physostigmine and lithium response in the schizophrenias. Am J Psychiatry (1981) 0.76
Negative symptoms of familial schizophrenia breed true in unstable (vs. stable) cerebral-ventricle pedigrees. Schizophr Res (1999) 0.76
Concentration of cholecystokinin in cerebrospinal fluid is decreased in psychosis: relationship to symptoms and drug response. Prog Neuropsychopharmacol Biol Psychiatry (1991) 0.76
Prediction of lithium carbonate dosage in psychiatric inpatients using the repeated one-point method. Clin Pharm (1983) 0.76
Growth hormone response to apomorphine and family patterns of illness. Biol Psychiatry (1987) 0.76
Impact of lithium therapy on core psychotic symptoms of schizophrenia. Br J Psychiatry (1984) 0.76
Clonazepam treatment of five lithium-refractory patients with bipolar disorder. Am J Psychiatry (1989) 0.76
Methodological issues facing the interpretation of high-risk studies: biological heterogeneity. Schizophr Bull (1987) 0.75
Progressive brain atrophy and VBR increase in schizophrenia? Acta Psychiatr Scand (2000) 0.75
Postsynaptic supersensitivity in schizophrenia. Am J Psychiatry (1977) 0.75
Schizophrenia and reduced cyclic AMP production: evidence for the role of receptor-linked events. Life Sci (1982) 0.75
Single- vs multiple-dose pharmacokinetics of clozapine in psychiatric patients. Pharm Res (1990) 0.75
SPECT studies of D2 occupancy in low-dose haloperidol treatment. Am J Psychiatry (1997) 0.75
CSF N-CAM in neuroleptic-naïve first-episode patients with schizophrenia. Schizophr Res (1998) 0.75
Growth hormone catecholamines in affective disease. Am J Psychiatry (1975) 0.75
Growth hormone levels and lithium ratios as predictors of success of lithium therapy in schizophrenia. Am J Psychiatry (1982) 0.75
Lithium response and psychoses: a double-blind, placebo-controlled study. Psychiatry Res (1984) 0.75
A psychobiologic perspective in treating psychiatric disorders. Compr Ther (1984) 0.75
Platelet monoamine oxidase activity in the psychoses: relationship to symptoms and lithium response. Psychiatry Res (1984) 0.75
Effect of carbidopa on the metabolism of L-dopa in the pigtail monkey. Biochem Pharmacol (1976) 0.75
Neuroendocrine and amine studies in affective illness. Psychoneuroendocrinology (1977) 0.75
Urinary cyclic AMP excretion by methadone subjects during gradual and acute withdrawal. Psychopharmacology (Berl) (1977) 0.75
Lithium ratio in vitro. Diagnosis and lithium carbonate response in psychotic patients. Arch Gen Psychiatry (1984) 0.75
Mood-incongruent versus mood-congruent psychosis: differential antipsychotic response to lithium therapy. Psychiatry Res (1984) 0.75
Fluphenazine plasma levels and clinical response. J Clin Psychiatry (1984) 0.75
Phenothiazine red cell levels and clinical response [proceedings]. Psychopharmacol Bull (1978) 0.75
Growth hormone response and central aminergic systems in affective diseases [proceedins]. Psychopharmacol Bull (1977) 0.75
Behavioral changes in a juvenile primate social colony with chronic administration of d-amphetamine. Psychopharmacol Commun (1976) 0.75
Adrenergic-receptor desensitization and course of clinical improvement with desipramine treatment. Psychopharmacology (Berl) (1984) 0.75
Therapeutic blood levels of fluphenazine: plasma or RBC determinations? Psychopharmacol Bull (1984) 0.75
Clinical relevance of thiothixene plasma levels. J Clin Psychopharmacol (1984) 0.75
Thioridazine effect on desipramine plasma levels. J Clin Psychopharmacol (1983) 0.75
Kinetic analysis of platelet monoamine oxidase in chronic schizophrenia. Life Sci (1981) 0.75
Dopamine and non-dopamine psychoses. Psychopharmacology (Berl) (1984) 0.75
Recent developments in the treatment of psychiatric disorders. Ohio State Med J (1984) 0.75
Combined thioridazine and desipramine: early antidepressant response. Psychopharmacology (Berl) (1984) 0.75